SecBot SecBot
8-K ·Filed Nov 12, 2026

AZTR

Azitra, Inc.
NEUTRAL
Impact 4/10
Horizonweeks Processed4d 23h ago SEC0001701478-26-000051
8-K Item 2.02: Earnings release
Actionable Insight • Neutral

Watch for topline data from ATR-04 Cohort 1 expected in Q4 2026 and initial results from the ATR-COSF first-in-human study by year-end 2026, as these could trigger additional financing from existing institutional investors. The company's cash position of $3.8M suggests a need for capital within the next 12 months absent new funding or milestone-driven investment.

DirectionNeutral
Confidencemedium
Horizonweeks

Drugs in focus

AZTR drug pipeline →

ATR-04

◆ Mixed Named in this 8-K
Impact
Phase
Phase 1/2
Time to market
Unknown — at least 3-5 years if Phase 1/2 data is positive, followed by Phase 3 trials and FDA review. The Fast Track designation could accelerate the timeline.
Next catalyst
None dated

What to watchWatch for ATR-04 Phase 1/2 first-cohort topline data expected Q4 2026, positive safety/efficacy signals could drive a sharp rally given the tiny market cap, but the ~6-month cash runway means a dilutive financing is likely before year-end regardless of results. The stock is a high-risk binary play on a single early-stage asset.

Price Chart

Loading chart...

Executive Summary

Azitra reported Q3 2026 results with a net loss of $3.0M, wider than the $2.8M loss in Q3 2025, and cash of $3.8M. The company highlighted progress in its ATR-04 Phase 1/2 trial (Cohort 1 completed, advancing to Cohort 2) and positive ex vivo data for ATR-COSF, with a first-in-human cosmetic study expected by year-end. No revenue was reported, and the net loss per share was $0.29.

Key Financial Metrics

EPS
−$0.29

Key Facts

  • Net loss of $3.0 million for Q3 2026, compared to $2.8 million in Q3 2025
  • Cash and cash equivalents of $3.8 million as of September 30, 2026
  • Completed Cohort 1 of ATR-04 Phase 1/2 trial; safety review committee recommended proceeding to Cohort 2
  • Expanded ATR-04 trial eligibility to include KRAS and MEK inhibitor-associated rash
  • Positive ex vivo results for ATR-COSF showing reduced fine lines and improved skin elasticity
  • First-in-human cosmetic study of ATR-COSF planned with initial results expected by year-end 2026
  • Institutional investors from March 2026 financing may invest an additional $5.25M to $10.5M upon ATR-COSF results announcement
  • R&D expenses $1.3 million vs $1.2 million in Q3 2025; G&A expenses $1.6 million vs $1.6 million
  • Weighted average shares outstanding 10,301,517 vs 411,769 in Q3 2025

Financial Impact

Net loss of $3.0 million, cash burn rate approximately $1.0 million per month, cash runway limited to roughly 3-4 quarters at current spend

net losscash and cash equivalentsoperating expenses

Risk Factors

  • Limited cash runway of $3.8 million may require additional financing within the next year
  • Clinical-stage biotech with no approved products or revenue; all programs are preclinical or early-stage clinical
  • Topline data from ATR-04 Cohort 1 and ATR-COSF study may not be favorable or may be delayed
  • Potential dilution from exercise of financial instruments issued in March 2026 private placement
  • High stock volatility (normal daily move of 18.9%) amplifies price sensitivity to binary clinical events

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001701478-26-000051
Document: aztr-20261112.htm0001701478-26-000051
Document: 0001701478-26-000051-index-headers.html0001701478-26-000051
Document: 0001701478-26-000051-index.html0001701478-26-000051
Document: 0001701478-26-000051.txt0001701478-26-000051
8-K Data (Synthetic)0001701478-26-000051

Track record

16 reports on AZTR

Performance horizon

2 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +38.73% at T+60 after the May 21, 2026 report. 3 of 3 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13D Neutral 5/10 Entry $0.5805 Now $0.6090 +4.91% settles Feb 16
  2. Nov 12, 20264d ago Press Release Neutral 4/10 Entry $0.6084 Now $0.6090 +0.10% settles Feb 11
  3. Nov 12, 20264d ago 8-K Neutral 4/10 Viewing No price data
  4. Nov 12, 20265d ago SC 13G/A Neutral 2/10 Entry $0.6685 Now $0.6090 −8.90% settles Feb 10
  5. Nov 10, 20267d ago 8-K Neutral 3/10 Entry $0.6000 Now $0.6090 +1.50% settles Feb 8
  6. Nov 10, 20267d ago Press Release Neutral 3/10 Entry $0.6000 Now $0.6090 +1.50% settles Feb 8
  7. Oct 29, 202619d ago 8-K Neutral 3/10 Entry $0.7571 Now $0.6090 −19.56% settles Jan 27
  8. Oct 26, 202622d ago 8-K Neutral 4/10 Entry $1.53 Now $0.6090 −60.20% settles Jan 22
  9. Oct 22, 202626d ago 8-K Neutral 3/10 Entry $0.0715 Now $0.6090 +751.75% settles Jan 21
  10. Oct 1, 20266w ago 8-K Neutral 4/10 Entry $0.1285 Now $0.6090 +373.93% settles Dec 28
Showing 10 of 16

US Market Status

Market Closed · Opens Wed (17h 28m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 12, 2026